Eam Investors, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Eam Investors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jul 12, 2023	SELL	$231.06 - $307.08 $21.8 Million - $28.9 Million	-94,265 Reduced 93.82%	6,205 $1.5 Million
Q1 2023 May 12, 2023	BUY	$231.06 - $307.08 $21.6 Million - $28.6 Million	93,272 Added 1295.8%	100,470 $24.3 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $420,291 - $2.13 Million	7,198 New	7,198 $2.09 Million
Q4 2018 Feb 13, 2019	SELL	$94.77 - $215.54 $1.2 Million - $2.74 Million	-12,699 Closed	0 $0
Q3 2018 Nov 08, 2018	SELL	$207.3 - $300.31 $1.62 Million - $2.34 Million	-7,807 Reduced 38.07%	12,699 $2.72 Million
Q2 2018 Aug 03, 2018	SELL	$101.55 - $313.9 $755,328 - $2.33 Million	-7,438 Reduced 26.62%	20,506 $5.74 Million
Q1 2018 May 14, 2018	SELL	$93.35 - $149.04 $1.58 Million - $2.53 Million	-16,945 Reduced 37.75%	27,944 $3.26 Million
Q4 2017 May 21, 2018	SELL	$39.35 - $97.37 $514,343 - $1.27 Million	-13,071 Reduced 22.55%	44,889 $4.12 Million
Q4 2017 Feb 12, 2018	BUY	$39.35 - $97.37 $2.28 Million - $5.64 Million	57,960	57,960 $5.32 Million

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.9B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.